Delivering Care Anywhere: Combining Technology and Home Trial Services to Enhance Clinical Trials

Key Takeaways

• Combining digital clinical trial technologies with Home Trial Services (HTS) allows appropriate assessments and procedures to move into the patient’s home while maintaining safety, data quality, and investigator oversight.

• Connected devices, electronic assessments, televisits, and wearables reduce travel and capture clinical trial data closer to when symptoms and events occur.

• HTS nurses bridge the gap between remote trial technology and patients’ real-world needs by providing clinical support, identifying potential concerns, and connecting home visits to the investigative site.

• Flexible clinical trial models must account for disease burden, mobility, digital literacy, device access, and connectivity to make participation practical for a broader range of patients.

Clinical trial participation requires patients to fit study activities into lives already shaped by illness, work, and family responsibilities. Repeated travel to an investigative site may become difficult as symptoms, mobility, or personal circumstances change. For sponsors and sites, these pressures create challenges in maintaining participation and completing protocol-required assessments throughout a study.

Digital technologies offer ways to conduct selected activities remotely, but moving an interaction online does not automatically make it easier for every patient. Device access, connectivity, and digital literacy influence whether a remote pathway is practical. Some activities also require hands-on clinical support. Sponsors must account for these needs while ensuring that assessments conducted outside the site meet study requirements for safety, data quality, and investigator oversight.

Combining digital technology with Home Trial Services (HTS) gives study teams more options for addressing these challenges. Planning both capabilities together allows appropriate activities to take place closer to the patient, with nursing support and clear connections to the investigative site. The starting point is to determine what each protocol activity requires and how patients will complete it reliably throughout the study.

Consider a protocol-required clinical trial visit conducted in the patient’s home. As part of the visit, a trained nurse completes required documentation and safety assessments and uses a connected device to collect a clinical-quality electrocardiogram. The reading may be transmitted through a cloud platform and made available for review by a cardiologist in real or near-real time. The patient completes the required study visit without traveling to a brick-and-mortar investigative site, while the assessment remains connected to appropriate specialist oversight.

This example illustrates the opportunity created when digital technology and HTS are designed as complementary parts of the same model. Technology supports communication, remote measurement, and timely data capture and transmission. HTS brings a trained clinical trial nurse into the participant’s home to perform delegated activities under the oversight of the principal investigator. Trained on the protocol and visit requirements, the nurse also supports the participant, recognizes and escalates potential safety or study-related concerns through established study processes, ensures appropriate documentation and data collection, and connects the home-based encounter to the investigative site and broader study team.

At Trialmed, we see the value of each capability become clearer when viewed through both the patient experience and successful trial execution. Electronic informed consent (eConsent), electronic clinical outcome assessments (eCOAs), televisits, wearables, and connected medical devices allow select protocol-required activities to be completed remotely, reducing the number of visits for which a patient must travel to and be physically present at the site. They may also capture symptoms or measurements closer to the time they occur rather than relying on recall during an intermittent appointment.

The value of those technologies depends on whether patients use them consistently and whether the resulting information enters the trial’s clinical and operational processes correctly. A device may collect the required measurement, but a patient may need help placing it, operating it, or determining what to do when it produces an unexpected result. An application may allow remote reporting, but the patient may struggle with authentication, connectivity, or instructions. HTS provides a human connection between a technology-enabled protocol and the circumstances in which patients actually participate.

Digital approaches are often introduced to reduce burden, but their convenience may be overstated when study design begins with what a platform does rather than what the intended population can realistically manage.

One study illustrates the problem. The protocol covered approximately 60 days and required daily contact, with patients traveling to the site once each week and completing most other visits through a telemedicine platform. On paper, the model offered a substantial benefit to an older population by replacing repeated travel with remote interactions. In practice, some participants had difficulty accessing the platform, remembering credentials, or navigating the application. At one point, the team found that approximately half of the participating patients did not have smartphones.

The study continued because several forms of support compensated for assumptions built into the original design. Nurses guided patients through the platform, technology teams provided assistance, and sites reinforced instructions during in-person visits. What appeared to be a simple remote pathway required continued human intervention to remain usable.

Digital trial design often assumes that patients have reliable internet access, suitable devices, and familiarity with applications, passwords, and electronic communication. Clinical trial populations may include older adults, children, and people with cognitive, visual, hearing, or motor limitations. Disease symptoms, fatigue, and treatment effects may also change a person’s ability to interact with technology over time.

Study teams should therefore evaluate digital burden across the entire patient journey. Removing a site visit may still add a device to charge, an application to monitor, another password to remember, and a helpdesk to contact. It may also shift work to caregivers, nurses, or site staff. The relevant question is whether the complete model makes participation more practical.

Patient, site, and HTS representatives may test proposed workflows before launch. Including HTS in this process ensures that home-based workflows are designed for both participants and the clinical trial nurses who will support them. Usability testing may uncover unclear instructions, inaccessible screens, burdensome authentication, or inadequate backup procedures. It may also confirm that HTS clinicians can access the required devices and platforms, receive appropriate accounts and permissions, complete necessary system training, and support participants with protocol-defined data collection and visit activities. Studies should also determine whether participants will use their own devices or receive provisioned equipment and what alternatives will be available when the intended pathway does not work.

HTS may provide an important layer of support without compromising the independence of patient-reported data. Nurses may be trained on the application or assessment platform to assist patients with accessing it, navigating its functions, or contacting the appropriate technical support team. They do not complete patient-reported questionnaires on the participant’s behalf. It is also important to distinguish among different types of assessments. Some are reported directly by the patient. Others require a trained clinician or rater to assign a classification according to defined criteria.

Potential adverse events follow another pathway. A nurse may ask open-ended questions, recognize that a symptom or change requires attention, and report it to the site. The investigator and study team then determine whether it constitutes an adverse event, establish its severity, and complete any required reporting. Clearly defining these roles ensures that required adverse-event screening remains part of the home visit while preserving the investigator’s responsibility for clinical evaluation, classification, and reporting.

Flexible trial delivery begins by examining the protocol activity by activity. Sponsors determine which activities genuinely must be performed at the site and which could be completed safely and reliably elsewhere.

Magnetic resonance imaging, biopsies, and procedures requiring specialized equipment or controlled conditions will generally remain at the site or another qualified facility. The presence of one site-based procedure, however, does not necessarily mean that every activity scheduled for the same visit must occur there. Blood collection, select vital signs, medication support, safety assessments, or other protocol procedures may be separated and completed closer to the patient when the protocol permits it.

This approach does not require every participant to follow the same pathway. In many studies, HTS is available as an optional service. The protocol identifies visits or activities that are eligible for remote delivery, the operational team prepares to support them, and the site and patient determine whether the option is appropriate. A participant may prefer a home visit for one activity and direct site contact for another. That preference may change during the study.

Planning for this choice is important because a patient’s circumstances rarely remain static. Health may improve or decline during the course of the clinical trial, which may take years to complete. Employment, transportation, or caregiving responsibilities may change. A participant who initially has no difficulty attending the site may later be unable to continue under the original schedule.

In one case, a participant had used all available paid time off during the main study and was preparing to decline participation in an open-label extension because returning to the site was no longer compatible with work. The study team arranged for a nurse to complete the visit at a private location at the participant’s workplace. The solution allowed the individual to remain in the study without leaving work for another site appointment.

Home services have also been introduced after a study begins to complete an existing final follow-up visit or support additional safety monitoring. These rescue applications preserve participation and prevent missing assessments. When additional safety monitoring requires new visits, however, a protocol amendment is typically necessary, with significant downstream effects on the study build, informed consent forms, clinical trial agreements, ethics review, contracting, and other operational processes. Incorporating appropriate options during protocol development creates a more efficient path if a patient later needs them.

Protocol flexibility only creates value when sites understand the service and present it to patients. Investigators may worry that home visits will weaken their relationship with participants or reduce their visibility into activities conducted outside the site. They may also have questions about nurse qualifications, delegation, documentation turnaround, and responsibility for scheduling or escalation. These concerns should be addressed during site selection and startup through specific oversight mechanisms. Sites can interview proposed HTS nurses, review their qualifications, and confirm processes for delegation, scheduling, documentation, and escalation. Telehealth visits provide additional oversight when appropriate, while direct communication before, during, and after each one keeps site staff informed. The HTS nurse functions as a remote member of the study site team under the principal investigator’s oversight, extending the site’s reach while the investigator retains accountability for study conduct and participant care.

Early planning should establish who may perform each activity, what equipment will be used, how information will return to the site, and what happens when the preferred pathway fails. The protocol, informed consent process, country feasibility assessment, and site preparation should all reflect the intended flexibility. Consent to the possibility of a home visit does not obligate a patient to use it. It preserves an option that may become important later.

Moving a trial activity beyond the site changes where it occurs, but it does not reduce the standards applied to the activity. Safety, documentation, and escalation processes must connect the remote encounter to the investigative site.

Safety communication is central to that model. When a nurse identifies a possible adverse event during a home visit, the usual process is to report it to the site in real time. The investigator or qualified site personnel evaluate the information, determine the appropriate classification, and decide what additional assessment or action is required. Predefined escalation pathways ensure that a concern observed in the home reaches the same clinical decisionmakers who would address it at the site.

Documentation must also support consistent review. Source worksheets are designed to align with the study’s case report forms so that information collected during a home visit corresponds to what site staff must enter into the electronic data capture system. Local-language materials, authenticated electronic signatures, and documented query-management processes support global consistency and inspection readiness.

Direct integration between remote source systems and electronic data capture platforms is not always available. In those cases, site staff review and enter information collected during the home visit, maintaining investigator visibility into activities conducted outside the facility. Clear documentation and data-transfer processes create a reliable information pathway that supports oversight and minimizes reconciliation work.

Contingency planning is equally important. A participant may lose connectivity while completing an electronic assessment, a device may fail to transmit, or a nurse may be working in an area without reliable internet access. Depending on the platform, an offline mode may retain responses until the connection is restored. Nurses may complete electronic worksheets locally and transmit them after returning to a connected location. Paper versions of the same materials may serve as a final backup.

These alternatives should be established before they are needed. A connectivity problem should not automatically become a missing-data problem, nor should technical difficulty force a participant to abandon an otherwise appropriate remote pathway.

Evaluating HTS against the needs it was designed to address allows sponsors to demonstrate its value and refine delivery. Relevant measures may include visit and assessment completion, patient and site feedback, technology support needs, data queries, and site workload. Study-level comparisons of retention, data completeness, and other outcomes can show where home-based pathways are most effective and inform future protocol design.

The value of a home visit extends beyond completing the protocol activity. Repeated visits may allow the patient to build a relationship with the same nurse, creating familiarity that supports more candid conversations and enables the nurse to recognize changes over time.

A patient may not think to report a gradual decline in mobility, a new difficulty with daily activities, or uncertainty about a symptom. During a home visit, the nurse has time to talk while collecting samples, performing assessments, or preparing medication. Details may emerge naturally that would not surface during a more compressed site appointment. The nurse may then document the concern and communicate it to the study team for evaluation.

The setting itself may also provide useful context. Blood pressure measured at home may be less affected by the anxiety associated with a clinical environment. A nurse may observe whether a patient has the supplies, dexterity, and confidence required to self-administer a therapy. Patients who appear comfortable after training at the site may encounter different questions when storing medication, preparing a dose, handling needles, or disposing of materials at home.

Growing familiarity with self-administered biologics is also changing how patients perform independently. A nurse may no longer need to administer every dose, but home support reinforces training and observation of the patient’s technique and determines whether the patient may continue safely without direct assistance. This illustrates how the role of HTS evolves as therapies and delivery technologies become easier to use.

Nurses may identify practical issues outside their immediate assigned task. A patient may mention that supplies have not arrived, express uncertainty about the next visit, or reveal that a change in work or family responsibilities is making participation difficult. These touchpoints create opportunities to address small problems before they become missed activities or reasons to withdraw.

Occasionally, the home environment may reveal a safeguarding concern or another issue requiring escalation. Nurses are provided clear guidance on what to document, whom to contact, and how to distinguish observation from clinical interpretation. Responsibility for evaluation and decision-making remains with the investigator and qualified site personnel.

For some families, the effect of home services is more fundamental. In one study involving two brothers with Duchenne muscular dystrophy, their increasing mobility limitations made weekly travel progressively harder for their mother. Travel support alone could not resolve the challenge of bringing both children to the site. She faced the possibility of withdrawing one child or removing both from the study. Because home visits were available, nurses could complete the required trial visits without forcing that decision.

Examples like this demonstrate why convenience may be an incomplete description. Avoiding travel may preserve access to a study when disease, family responsibilities, or employment would otherwise make participation unsustainable.

Global studies require consistent procedures and data regardless of where an activity occurs. Protocol-specific training, assessment methods, equipment, worksheets, and escalation processes remain aligned across countries. That consistency gives nurses clear parameters for each visit and enables sites a better understanding of what to expect from remotely conducted activities.

Local delivery still matters. Language, cultural expectations, and professional-practice rules affect how a patient experiences a home visit. Local nurses understand how to introduce themselves, communicate with families, and navigate expectations that may not be apparent to a centrally managed team. They may also identify assumptions in the proposed workflow that do not fit local practice.

Acceptance of HTS varies. At Trialmed, our experience has included increasing activity across European and Asia-Pacific countries, with early operational and regulatory preparation particularly important in markets such as Japan and China. In some Eastern European countries and sites, we have encountered greater resistance to nurse-led activities in the home, particularly blood collection or administration of an investigational product.

These differences do not arise from regulation alone. Ethics committees, institutional policies, contracting requirements, liability arrangements, professional-practice norms, and individual investigator preferences may all shape what is possible. Even within the same country, one site may readily accept a remote model while another requires additional agreements or declines to participate.

Country and site feasibility should therefore begin early. A global protocol designed for flexible delivery permits different levels of use across locations while preserving consistent scientific requirements. Study teams preserve consistent scientific requirements while adapting the operating model to local rules and clinical practice.

Wearables, connected medical devices, and artificial intelligence (AI)-supported systems will continue to expand the range of information that is collected outside the site. New platforms may simplify data transmission, support more continuous monitoring, and allow specialists to review results more quickly. These developments will increase the number and complexity of trial activities that potentially occur in the home.

Advancing technology will strengthen and refine the role of the HTS nurse. By automating some routine steps, digital tools allow nurses to focus more closely on patient education, correct device use, clinical observation, and escalation. As the volume and frequency of remotely collected data increase, the nurse connects those measurements with the patient’s condition and circumstances and ensures that relevant context reaches the investigative site.

The patients most likely to benefit from flexible delivery may also be managing complex disease, comorbidities, mobility restrictions, cognitive limitations, or symptoms that fluctuate over time. The trained HTS nurse provides a consistent clinical touchpoint, enabling the patient to navigate required visit activities, observing changes in their condition, and maintaining direct communication with the investigative site. When illness or symptoms affect what the participant manages on a particular day, the nurse will recognize and escalate the issue through established study processes.

Future trial models will move beyond fixed distinctions among site-based, decentralized, and hybrid studies. A well-designed protocol integrates site visits, digital interactions, connected devices, and HTS within a coordinated delivery model built around the participant. For each activity, the protocol defines the setting and delivery method needed for safe, reliable execution with the least unnecessary burden. Throughout the study, the HTS nurse, technology platforms, devices, and investigative site remain connected through shared workflows, clear communication, and investigator oversight, allowing participation to move across settings without fragmenting the patient experience or trial conduct.

When these elements are planned as one system, HTS extends the investigative site’s reach into the home, reduces travel burden, and supports continuity throughout the participant’s experience. Protocol-required activities occur closer to the patient while maintaining safety, data quality, investigator oversight, and connection to the broader study team.